Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26439684 | 1.00 | TDP1 (0.41) | TDP1MEN1KMT2ATHRBCYP2D6 | |
| SCHEMBL30413301 | 1.00 | TDP1 (0.41) | TDP1MEN1KMT2ATHRBCYP2D6 | |
| SCHEMBL25746396 | 1.00 | TDP1 (0.41) | TDP1MEN1KMT2ATHRBCYP2D6 | |
| Hydrochloric Acid SCHEMBL25332412 | 0.97 | TDP1 (0.40) | TDP1MEN1KMT2ATHRBCYP2D6 | |
| Hydrochloric Acid SCHEMBL26094931 | 0.97 | TDP1 (0.40) | TDP1MEN1KMT2ATHRBCYP2D6 | |
| Hydrochloric Acid SCHEMBL25332416 | 0.97 | TDP1 (0.40) | TDP1MEN1KMT2ATHRBCYP2D6 | |
| SCHEMBL1697382 | 0.95 | TDP1 (0.48) | TDP1MEN1KMT2ATHRBCYP2D6 | |
| SCHEMBL20752154 | 0.95 | TDP1 (0.48) | TDP1MEN1KMT2ATHRBCYP2D6 | |
| Hydrochloric Acid SCHEMBL31021485 | 0.93 | TDP1 (0.47) | TDP1MEN1KMT2ATHRBCYP2D6 | |
| SCHEMBL3076098 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | TDP1 964/4885MEN1 3585/4885KMT2A 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.